A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 384 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of ‘Low-Alcohol’ Labelling in Response to the Council Agreement on the EU’s Wine Package MOST POPULAR Coronavirus and cancer – July updates July 7, 2020 Coping With Life After a Bone Marrow Transplant: A Survivor’s Story August 15, 2023 Female Representation at the Top of the Oncology Field Has Hit... October 20, 2021 A Pet Pug Helped Two Sisters Realize They Both Had Breast... October 16, 2020 Load more HOT NEWS Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced... Prize winning early detection research Oncolytic Virus Enables the Immune System to Attack Tumors FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib...
